Fraunhofer iCAIRTM is breaking new ground in the development of antiviral drugs

In the project Fraunhofer iCAIRTM, the Fraunhofer International Consortium for Anti-Infective Research, scientists of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Australia's Institute for Glycomics (IfG) of Griffith University, Queensland, and the Hannover Medical School have teamed up to explore novel anti-infective therapeutic concepts.

They identify therapeutic targets, develop compounds acting on these targets, and evaluate the efficacy of these drug candidates in special test systems such as PCLS – lung slices created from resected human lung tissue. During this year’s International Conference of the American Thoracic Society (ATS) in Dallas, TX (USA), the researchers showed that this test system can also be used for efficacy testing of novel anti-influenza drugs ((link to Olga’s ATS abstract)).

They demonstrated that zanamivir, an already approved neuraminidase inhibitor developed by the Australian researchers, has the same antiviral effect in human PCLS infected with influenza virus ex vivo as in the intact human organism. Human PCLS can thus be used for preclinical efficacy testing of novel antiviral drugs in the future. The Fraunhofer scientists are currently testing new active agents developed at IfG in the PCLS model.

The overall aim of the scientists in the project Fraunhofer iCAIRTM is to overcome one of the biggest obstacles to developing new drugs: the gap in the drug development chain that arises between the discovery of new, potentially beneficial substances – often by universities or small companies – and the clinical development up to approval of a new drug, carried out by pharmaceutical companies.

Once a drug candidate has been identified, it first has to undergo preclinical testing in relevant and predictive test systems, before it can advance to the stage of clinical testing. Fraunhofer iCAIRTM, with its broad interdisciplinary expertise ranging from basic research to preclinical testing, aims to bridge this gap in the drug development process and to help meet the urgent need for new anti-infective drugs.

The aims, possibilities and services offered by Fraunhofer iCAIRTM will also be presented at the Fraunhofer booth in the German Pavillon at this year’s BIO International Convention, the world's largest biotechnology trade fair, taking place in Philadelphia, PA (USA) from June 3 to 6.

Press contact:
Fraunhofer ITEM
Dr. Cathrin Nastevska
cathrin.nastevska@item.fraunhofer.de

Dr. Jana Führing
jana.fuehring@item.fraunhofer.de

https://www.item.fraunhofer.de/en.html
https://www.item.fraunhofer.de/en/lighthouse-projects/icair-project.html
https://www.griffith.edu.au/institute-glycomics
https://www.mh-hannover.de/index.php?id=36255&L=1
https://www.abstractsonline.com/pp8/#!/5789/presentation/9948

Media Contact

Dr. Cathrin Nastevska Fraunhofer-Gesellschaft

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Kidney disease, Chronic kidney disease ckd, Doctor with human model to study and treat in hospital.

New Study Offers Hope for Chronic Pain Relief in Dialysis Patients

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it can be difficult to manage with opioid medication and other conventional treatments. A…

Early Adult Mortality Surges in Post-COVID US

Early Adult Mortality Surges in Post-COVID US

New research from Boston University School of Public Health and the University of Minnesota shows that death rates for early adults, or adults aged 25-44, rose sharply during the COVID-19…

Stanford associate professor William Tarpeh and PhD student Samantha Bunke working in the Tarpeh lab. Image Credit: Bill Rivard/Precourt Institute for Energy, Stanford University

Recycling Lithium-Ion Batteries Boosts Supply Chain Resilience

Recycling lithium-ion batteries to recover their critical metals has significantly lower environmental impacts than mining virgin metals, according to a new Stanford University lifecycle analysis published in Nature Communications. On…